Cambridge Investment Research Advisors Inc. Invests $219,000 in Nektar Therapeutics (NKTR) Stock

Cambridge Investment Research Advisors Inc. acquired a new position in Nektar Therapeutics (NASDAQ:NKTR) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 3,666 shares of the biopharmaceutical company’s stock, valued at approximately $219,000.

Other institutional investors have also recently bought and sold shares of the company. BB&T Investment Services Inc. acquired a new position in Nektar Therapeutics in the 4th quarter worth approximately $119,000. Meeder Asset Management Inc. acquired a new position in Nektar Therapeutics in the 4th quarter worth approximately $121,000. Oppenheimer Asset Management Inc. acquired a new position in Nektar Therapeutics in the 3rd quarter worth approximately $129,000. Certified Advisory Corp acquired a new position in Nektar Therapeutics in the 4th quarter worth approximately $148,000. Finally, SeaCrest Wealth Management LLC acquired a new position in Nektar Therapeutics in the 4th quarter worth approximately $200,000. 96.32% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

NKTR has been the subject of a number of recent analyst reports. HC Wainwright set a $125.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Monday, April 9th. Jefferies Group raised their price objective on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday, January 16th. BidaskClub raised shares of Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 21st. Zacks Investment Research raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 21st. Finally, Cowen reaffirmed a “buy” rating and issued a $101.00 price objective on shares of Nektar Therapeutics in a research note on Friday, March 2nd. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $71.75.

In other Nektar Therapeutics news, CEO Howard W. Robin sold 83,333 shares of Nektar Therapeutics stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $75.82, for a total transaction of $6,318,308.06. Following the completion of the sale, the chief executive officer now owns 333,268 shares of the company’s stock, valued at approximately $25,268,379.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Stephen K. Doberstein sold 2,426 shares of Nektar Therapeutics stock in a transaction on Friday, February 16th. The shares were sold at an average price of $82.94, for a total transaction of $201,212.44. Following the sale, the senior vice president now directly owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The disclosure for this sale can be found here. Insiders have sold a total of 588,473 shares of company stock valued at $54,878,447 in the last three months. Company insiders own 5.44% of the company’s stock.

Shares of NASDAQ:NKTR opened at $92.54 on Thursday. The firm has a market cap of $15,041.46, a price-to-earnings ratio of -168.25 and a beta of 1.74. Nektar Therapeutics has a 12-month low of $17.33 and a 12-month high of $111.36. The company has a debt-to-equity ratio of 2.79, a current ratio of 5.82 and a quick ratio of 5.63.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.14. The company had revenue of $95.47 million during the quarter, compared to analyst estimates of $36.96 million. Nektar Therapeutics had a negative net margin of 31.42% and a negative return on equity of 156.85%. The company’s revenue for the quarter was up 154.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.28) EPS. equities analysts forecast that Nektar Therapeutics will post -1.43 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Cambridge Investment Research Advisors Inc. Invests $219,000 in Nektar Therapeutics (NKTR) Stock” was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://weekherald.com/2018/04/19/cambridge-investment-research-advisors-inc-invests-219000-in-nektar-therapeutics-nktr-stock.html.

Nektar Therapeutics Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply